A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE

Discrepancies between one stage assay and chromogenic substrate assay in patients treated with recombinant or plasma-derived FVIII and usefulness of a specific standard in ReFacto AF®-treated patients

(2016) C. Pouplard et al.   HAEMOPHILIA

BAY 81-8973, a full-length recombinant factor VIII: results from an International comparative laboratory field study

(2016) S. Kitchen et al.   HAEMOPHILIA

A computer-based model to assess costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assays

(2016) S. Kitchen et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

A critical appraisal of one-stage and chromogenic assays of factor VIII activity

(2016) F. Peyvandi et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Development, Validation, and Application of a Novel Ligand-Binding Assay to Selectively Measure PEGylated Recombinant Human Coagulation Factor VIII (BAX 855)

(2015) Alfred Weber et al.   BIOCONJUGATE CHEMISTRY

One-stage vs. chromogenic assays in haemophilia A

(2015) Joachim J. Potgieter et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Porcine recombinant factor VIII (Obizur; OBI-1; BAX801): product characteristics and preclinical profile

(2015) D. Lillicrap et al.   HAEMOPHILIA

Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A

(2015) R. Kruse-Jarres et al.   HAEMOPHILIA

Safety of PEGylated recombinant human full-length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugates

(2015) R. Stidl et al.   HAEMOPHILIA

Current laboratory practices in the diagnosis and management of haemophilia: a global assessment

(2015) S. Kitchen et al.   HAEMOPHILIA

Monitoring of modified factor VIII and IX products

(2014) S. Kitchen et al.   HAEMOPHILIA

The biological efficacy profile of BAX 855, a PEGylated recombinant factor VIII molecule

(2014) L. A. Valentino et al.   HAEMOPHILIA

Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94-9027) for haemophilia A

(2014) J-M. Gu et al.   HAEMOPHILIA

Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity

(2014) Yang Buyue et al.   THROMBOSIS AND HAEMOSTASIS

Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories

(2013) J. M. Sommer et al.   HAEMOPHILIA

Recommendations on the potency labelling of factor VIII and factor IX concentrates

(2013) A. R. Hubbard et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

New cell line development for antibody-producing Chinese hamster ovary cells using split green fluorescent protein

(2012) Yeon-Gu Kim et al.   BMC BIOTECHNOLOGY

Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A

(2012) C. L. KEMPTON et al.   HAEMOPHILIA

International comparative field study of N8 evaluating factor VIII assay performance

(2011) D. VIUFF et al.   HAEMOPHILIA

The between-Laboratory Variation of Factor VIII Inhibitor Testing: The Experience of the External Quality Assessment Program of the ECAT Foundation

(2010) Piet Meijer et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Interlaboratory Variation in Factor VIII:C Inhibitor Assay Results Is Sufficient to Influence Patient Management: Data from the UK National Quality External Assessment Scheme for Blood Coagulation

(2010) Steve Kitchen et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Performance of recalibrated ReFacto®laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one-stage assays after infusion of recalibrated ReFacto®(B-domain deleted recombinant factor VIII)

(2009) C. SANTORO et al.   HAEMOPHILIA